SEARCH

SEARCH BY CITATION

References

  • 1
    Miki Y,Swensen J,Shattuck-Eidens D,Futreal PA,Harshman K,Tavtigian S,Liu Q,Cochran C,Bennett LM,Ding W,Bell R,Rosenthal J, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 6671.
  • 2
    Wooster R,Bignell G,Lancaster J,Swift S,Seal S,Mangion J,Collins N,Gregory S,Gumbs C,Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 78992.
  • 3
    Struewing JP,Hartge P,Wacholder S,Baker SM,Berlin M,McAdams M,Timmerman MM,Brody LC,Tucker MA. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336: 14018.
  • 4
    Claus EB,Schildkraut JM,Thompson WD,Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer 1996; 77: 231824.
  • 5
    Chen S,Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007; 25: 132933.
  • 6
    Cohen CJ,Jennings TS. Screening for ovarian cancer: the role of noninvasive imaging techniques. Am J Obstet Gynecol 1994; 170: 108894.
  • 7
    Pharoah PD,Easton DF,Stockton DL,Gayther S,Ponder BA. Survival in familial, BRCA1-associated, BRCA2-associated epithelial ovarian cancer. United Kingdom coordinating committee for cancer research (UKCCCR) familial ovarian cancer study group. Cancer Res 1999; 59: 86871.
  • 8
    Shaw PA,McLaughlin JR,Zweemer RP,Narod SA,Risch H,Verheijen RH,Ryan A,Menko FH,Kenemans P,Jacobs IJ. Histopathologic features of genetically determined ovarian cancer. Int J Gynecol Pathol 2002; 21: 40711.
  • 9
    Werness BA,Ramus SJ,Whittemore AS,Garlinghouse-Jones K,Oakley-Girvan I,Dicioccio RA,Tsukada Y,Ponder BA,Piver MS. Histopathology of familial ovarian tumors women from families with and without germline BRCA1 mutations. Hum Pathol 2000; 31: 14204.
  • 10
    Hogg R,Friedlander M. Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. J Clin Oncol 2004; 22: 131527.
  • 11
    Lakhani SR,Manek S,Penault-Llorca F,Flanagan A,Arnout L,Merrett S,McGuffog L,Steele D,Devilee P,Klijn JG,Meijers-Heijboer H,Radice P, et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res 2004; 10: 247381.
  • 12
    Hermsen BB,Olivier RI,Verheijen RH,Van Beurden M,De Hullu JA,Massuger LF,Burger CW,Brekelmans CT,Mourits MJ,De Bock GH,Gaarenstroom KN,Van Boven HH, et al. No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. Br J Cancer 2007; 96: 133542.
  • 13
  • 14
    Sassone AM,Timor-Tritsch IE,Artner A,Wetshoff C,Warren WB. Transvaginal sonographic characterization of ovarian disease: evaluation of a new scoring system to predict ovarian malignancy. Obstet Gynecol 1991; 78: 706.
  • 15
    Muto MG,Cramer DW,Brown DL,Welch WR,Harlow BL,Xu H,Brucks JP,Tsao SW,Berkowitz RS. Screening for ovarian cancer: the preliminary experience of a familial ovarian cancer center. Gynecol Oncol 1993; 51: 1220.
  • 16
    Mann WJ,Patsner B,Coher H,Loesch M. Preoperative serum CA-125 levels in patients with surgical stage I invasive ovarian adenocarcinoma. J Natl Cancer Inst 1998; 80: 20813.
  • 17
    Jacobs I,Bast RC,jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989; 4: 15
  • 18
    Oei AL,Massuger LF,Bulten J,Ligtenberg MJ,Hoogerbrugge N,de Hullu JA. Surveillance of women at high risk for hereditary ovarian cancer is inefficient. Br J Cancer 2006; 94: 81419.
  • 19
    Gaarenstroom KN,Van der Hiel B,Tollenaar RAEM,Vink GR,Jansen FW,Van Asperen CJ,Kenter GG. Efficacy of screening at high risk of hereditary ovarian cancer: results of an 11-year cohort study. Int J Gynecol Cancer 2006; 16: 549.
  • 20
    Olivier RI,Lubsen-Brandsma MAC,Verhoef S,Van Beurden M. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol 2006; 100: 206.
  • 21
    Vasen HFA,Tesfay E,Boonstra H,Mourits MJ,Rutgers E,Verheyen R,Oosterwijk J,Beex L. Early detection of breast and ovarian cancer in families with BRCA mutations. Eur J Cancer 2005; 41: 54954.
  • 22
    Meeuwissen PAM,Seynaeve C,Brekelmans CTM,Meijers-Heijboer HJ,Klijn JGM,Burger CW. Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer. Gynecol Oncol 2005; 97: 47682.
  • 23
    Stirling D,Evans DG,Pichert G,Shenton A,Kirk EN,Rimmer S,Steel CM,Lawson S,Busby-Earle RM,Walker J,Lalloo FI,Eccles DM, et al. Screening for familial ovarian cancer failure of current protocols to detect ovarian cancer at an early stage according to the international federation of gynecology and obstetrics system. J Clin Oncol 2005; 23: 558896.
  • 24
    Laframboise S,Nedelcu R,Murphy J,Cole DEC,Rosen B. Use of CA-125 and ultrasound in high-risk women. Int J Gynecol Cancer 2002; 12: 8691.
  • 25
    Scheuer L,Kauff N,Robson M,Kelly B,Barakat R,Satagopan J,Ellis N,Hensley M,Boyd J,Borgen P,Norton L,Offit K. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 2002; 20: 12608.
  • 26
    Dørum A,Heimdal K,Løvslett K,Kristensen G,Hansen LJ,Sandvei R,Schiefloe A,Hagen B,Himmelmann A,Jerve F,Shetelig K,Fjaerestad I, et al. Prospectively detected cancer in familial breast/ovarian cancer screening. Acta Obstet Gynecol Scand 1999; 78: 90611.
  • 27
    Bosse K,Rhiem K,Wappenschmidt B,Hellmich M,Madeja M,Ortmann M,Mallmann P,Schmutzler R. Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: a prospective cohort study. Gynecol Oncol 2006; 103: 107782.
  • 28
    Jacobs IJ,Skates SJ,MacDonald N,Menon U,Rosenthal AN,Davies AP,Woolas R,Jeyarajah AR,Sibley K,Lowe DG,Oram DH. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999; 353: 120710.
  • 29
    Bast RC,Jr,Brewer M,Zou C,Hernandez MA,Daley M,Ozols R,Lu K,Lu Z,Badgwell D,Mills GB,Skates S,Zhang Z, et al. Prevention and early detection of ovarian cancer: mission impossible? Recent Results Cancer Res 2007; 174: 91100.
  • 30
    Zhang Z,Yu Y,Xu F,Berchuck A,Van Haaften-Day C,Havrilesky LJ,De Bruijn HW,Van der Zee AG,Woolas RP,Jacobs IJ,Skates S,Chan DW, et al. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol 2007; 107: 52631.
  • 31
    Liu C,Shea N,Rucker S,Harvey L,Russo P,Saul R,Lopez MF,Mikulskis A,Kuzdzal S,Golenko E,Fishman D,Vonderheid E, et al. Proteomic patterns for classification of ovarian cancer and CTCL serum samples utilizing peak pairs indicative of post-translational modifications. Proteomics 2007; 7: 404552.
  • 32
    Kauff ND,Satagopan JM,Robson ME,Scheuer L,Hensley M,Hudis CA,Ellis NA,Boyd J,Borgen PI,Barakat RR,Norton L,Castiel M, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346: 160915.
  • 33
    Rebbeck TR,Lynch HT,Neuhausen SL,Narod SA,Van't Veer L,Garber JE,Evans G,Isaacs C,Daly MB,Matloff E,Olopade OI,Weber BL. Prevention and observation of surgical end points study group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346: 161622
  • 34
    Meijers-Heijboer EJ,Verhoog LC,Brekelmans CTM,Seynaeve C,Tilanus-Linthorst MM,Wagner A,Dukel L,Devilee P,van den Ouweland AM,van Geel AN,Klijn JG. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA 2 mutation. Lancet 2000; 335: 201520.